Please use this identifier to cite or link to this item: https://oxfordhealth-nhs.archive.knowledgearc.net/handle/123456789/716
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHarrison, Paul J-
dc.contributor.authorColbourne, Lucy-
dc.date.accessioned2021-02-03T15:37:53Z-
dc.date.available2021-02-03T15:37:53Z-
dc.date.issued2021-01-
dc.identifier.citationHarrison, P., Colbourne, L., & Luciano, S. (2021). Incidence of neurodegenerative and cerebrovascular diseases associated with antihypertensive drug classes. The British Journal of Psychiatry, 1-3.en
dc.identifier.issn1472-1465-
dc.identifier.urihttps://oxfordhealth-nhs.archive.knowledgearc.net/handle/123456789/716-
dc.descriptionAvailable with an OpenAthens log in for eligible usersen
dc.description.abstractAntihypertensive drugs (AHTs) are associated with lowered risks of neurodegenerative diseases and stroke. However, the relative risks associated with different AHT classes are unclear. Using an electronic health record network with 34 million eligible patients, we compared rates of these disorders over a 2-year period, in propensity score-matched cohorts of people taking calcium channel blockers (CCBs) compared with those taking other AHT classes. CCBs were associated with a higher incidence of all disorders compared with renin-angiotensin system agents, and a higher incidence of dementia and cerebrovascular disease compared with diuretics. CCBs were associated with a lower incidence of movement disorders and cerebrovascular disease compared with beta-blockers. The data show that AHT classes confer differential risks of neurodegenerative and cerebrovascular diagnoses.en
dc.description.urihttps://doi.org/10.1192/bjp.2020.249en
dc.language.isoenen
dc.titleIncidence of neurodegenerative and cerebrovascular diseases associated with antihypertensive drug classesen
dc.typeArticleen
Appears in Collections:Dementia

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.